Caffeine Suppresses Amyloid-β Levels in Plasma and Brain of Alzheimer’s Disease Transgenic Mice

Chuanhai Cao\textsuperscript{a,b}, John R. Cirrito\textsuperscript{c}, Xiaoyang Lin\textsuperscript{a,b}, Lilly Wang\textsuperscript{b,d}, Deborah K Verges\textsuperscript{e}, Alexander Dickson\textsuperscript{b,d}, Malgorzata Mamcarz\textsuperscript{b,d}, Chi Zhang\textsuperscript{a,b}, Takashi Mori\textsuperscript{e}, Gary W. Arendash\textsuperscript{b,d,*}, David M. Holtzman\textsuperscript{c,f,g} and Huntington Potter\textsuperscript{a,b,h}

\textsuperscript{a}The Byrd Alzheimer’s Center & Research Institute, Tampa, FL, USA
\textsuperscript{b}Florida Alzheimer’s Disease Research Center, University of South Florida, Tampa, FL, USA
\textsuperscript{c}Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
\textsuperscript{d}Department of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, FL, USA
\textsuperscript{e}Departments of Medical Science and Pathology, Saitama Medical Center and Saitama Medical University, Kawagoe, Saitama, Japan
\textsuperscript{f}Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA
\textsuperscript{g}Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA
\textsuperscript{h}Suncoast Gerontology and Alzheimer’s Center, University of South Florida College of Medicine, Tampa, FL, USA

Abstract. Recent epidemiologic studies suggest that caffeine may be protective against Alzheimer’s disease (AD). Supportive of this premise, our previous studies have shown that moderate caffeine administration protects/restores cognitive function and suppresses brain amyloid-β (Aβ) production in AD transgenic mice. In the present study, we report that acute caffeine administration to both young adult and aged AD transgenic mice rapidly reduces Aβ levels in both brain interstitial fluid and plasma without affecting Aβ elimination. Long-term oral caffeine treatment to aged AD mice provided not only sustained reductions in plasma Aβ, but also decreases in both soluble and deposited Aβ in hippocampus and cortex. Irrespective of caffeine treatment, plasma Aβ levels did not correlate with brain Aβ levels or with cognitive performance in individual aged AD mice. Although higher plasma caffeine levels were strongly associated with lower plasma Aβ\textsubscript{1-40} levels in aged AD mice, plasma caffeine levels were also not linked to cognitive performance. Plasma caffeine and theophylline levels were tightly correlated, both being associated with reduced inflammatory cytokine levels in hippocampus. Our conclusion is two-fold: first, that both plasma and brain Aβ levels are reduced by acute or chronic caffeine administration in several AD transgenic lines and ages, indicating a therapeutic value of caffeine against AD; and second, that plasma Aβ levels are not an accurate index of brain Aβ levels/deposition or cognitive performance in aged AD mice.

Keywords: Alzheimer’s disease, amyloid-β, brain interstitial fluid, caffeine, plasma, transgenic mice

INTRODUCTION

Synthetic anti-Alzheimer’s disease (AD) drugs currently on the market have mild symptomatic benefits, are not known to be disease-modifying, and can have significant undesirable side-effects. Thus, it would be most desirable to identify an inherently safe and readily available “nutriceutic” compound (e.g., natural and normally in the diet) that can provide therapeutic utility against AD. Caffeine is a methylxanthine, highly concentrated in coffee, and probably the world’s most widely consumed psychoactive substance [1]. The well known ability of caffeine to increase alert-
ness and arousal primarily involves antagonism of central nervous system adenosine receptors, while additional mechanisms of caffeine action (e.g., phosphodiesterase inhibition, calcium mobilization) have been proposed [2], although they occur only at high, unphysiologic concentrations of caffeine (mM range). Oral caffeine is rapidly and almost completely absorbed via the gastrointestinal tract, with blood caffeine levels quickly equilibrating with brain tissue levels due to caffeine’s unhindered traversal of the blood-brain barrier [3,4]. Caffeine is primarily metabolized in the liver to theophylline and paraxanthine, both of which are at least as physiologically active as caffeine [3]. There are no apparent differences in metabolism of, or physiological responses to, caffeine in elder individuals compared to young individuals; moreover, caffeine’s pharmacokinetics are similar after oral or intravenous administration in humans and animals [3].

Recent longitudinal studies spanning 4–10 years suggest that habitual caffeine/coffee intake protects against cognitive impairment in aging humans [5,6]. Moreover, an epidemiologic study evaluated caffeine intake during the 20 years preceding AD diagnosis and found that AD patients consumed markedly less caffeine during that period compared to age-matched individuals without AD [7]. Collectively, these and other observational human studies [8] suggest that habitual caffeine/coffee intake may protect against memory impairment and AD during aging. However, because such studies are not controlled and cannot isolate the effect of caffeine from the myriad of other lifestyle choices humans make, we performed a highly controlled “protection-based” study in mice [9]. In that study, we found that oral caffeine administration to AD transgenic (APPsw) mice from young adulthood into older age: 1) protected these mice from otherwise certain cognitive impairment in older age; and 2) limited their brain production of the peptide amyloid-\(\beta\) (A\(\beta\)). The moderate amount of caffeine intake given to these APPsw mice (human equivalency of 5 cups of coffee per day) suppressed both \(\beta\)-secretase (BACE1) and \(\gamma\)-secretase/PS1 levels in hippocampus, indicating that caffeine can directly impact AD pathogenesis in these AD mice. This study in AD mice is consistent with the human epidemiologic literature supporting an ability of moderate caffeine intake to reduce risk of AD [7]. Paradoxically, human intake of coffee/caffeine declines appreciably during aging in Western cultures, in part due to caffeine intake restrictions often suggested by health care professions. Such restrictions would appear unwarranted, based on comprehensive literature searches indicating that moderate caffeine intake has no adverse effects on the cardiovascular system, bone status, calcium balance, or the incidence of cancer during aging [4,10]. Indeed, a recent study involving 18–24 year follow-ups found that coffee intake (4–6 cups per day) was associated with reduced mortality, particularly due to cardiovascular disease [11].

The potential for caffeine to treat established AD has yet to be explored in human studies. As an initial step for elucidating possible efficacy of caffeine to stabilize or reverse established AD, we have recently completed a “treatment-based” study in aged APPsw mice that already contained A\(\beta\) pathology (see accompanying paper [12]). These aged mice were confirmed to be cognitively impaired in working memory prior to receiving several months of oral caffeine treatment. When re-tested, aged APPsw mice receiving caffeine treatment exhibited working memory that was not only substantially better than APPsw mice that did not receive caffeine, but comparable to normal nontransgenic mice [12]. Thus, even with pre-existing and substantial A\(\beta\) neuropathology, aged APPsw mice exhibited memory restoration with caffeine treatment, suggesting a therapeutic potential of caffeine in cases of established AD.

Substantial evidence suggests that the brain’s production and aggregation of A\(\beta\) peptide represent key events underlying AD pathogenesis. As depicted in Fig. 1A, newly produced A\(\beta\) enters a dynamic equilibrium between soluble and deposited A\(\beta\) in the brain, with continual transport of soluble A\(\beta\) out of the brain and into plasma. In view of our findings that caffeine decreases A\(\beta\) production in APPsw mice through suppression of both BACE1 and \(\gamma\)-secretase/PS1 [9], we hypothesize that resultant lower brain levels of soluble A\(\beta\) will at least acutely result in lower plasma A\(\beta\) levels (Fig. 1B). This hypothesis is supported by the finding that A\(\beta\) is rapidly produced and cleared from the brain [13]. In the present study, we determine the effect of both acute and chronic caffeine administration on plasma and brain A\(\beta\) levels in AD mice. In addition, we explore possible relationships between: 1) plasma and brain pools of A\(\beta\); 2) plasma caffeine/theophylline concentrations and plasma/plasma A\(\beta\) levels; and 3) plasma A\(\beta\)/caffeine levels and cognitive performance. Possible associations between A\(\beta\), caffeine, and cytokines are also considered. Both young adult and aged AD mice were utilized in these studies to investigate the effect of caffeine at both early (pre-A\(\beta\) deposition) and late (robust A\(\beta\) deposition) stages of the disease in mice.
Fig. 1. Diagrams depicting brain Aβ production/clearance, the suppressive actions of caffeine on Aβ production, and resultant effects on brain and plasma Aβ levels. (A) Unmodulated: Aβ is primarily produced in neurons, secreted into the brain extracellular space in soluble form, then enters a dynamic equilibrium between soluble and deposited (insoluble) Aβ. Continual transport of soluble Aβ occurs into plasma. (B) Caffeine: Short-Term: Caffeine suppression of both β- and γ-secretase activities reduces Aβ production, resulting in lower soluble Aβ in brain and plasma. The equilibrium between soluble and deposited Aβ is not impacted by this short-term reduction in brain soluble Aβ levels. (C) Caffeine: Long-Term: Continued caffeine suppression of Aβ production and resultant lower levels of brain soluble Aβ induce a flux of deposited (insoluble) Aβ to the soluble form, which is cleared from brain into plasma via soluble Aβ transport. Plasma Aβ levels may be reduced or not changed, depending on degree of caffeine-induced suppression of Aβ production. In aged APPsw mice given chronic caffeine treatment, their lower brain Aβ levels/deposition results in reversal of cognitive dysfunction. (Colours are visible in the electronic version of the article at www.iospress.nl.)

Based on encouraging results from our completed caffeine administration studies in AD transgenic mice [9,12], clinical trials in aged individuals are currently being conducted to investigate the effects of caffeine administration on plasma Aβ levels. As such, a major aim of the present study was to attain advance insight into potential results from those clinical trials through similar studies in AD transgenic mice.

MATERIAL AND METHODS

Animals

In these studies, all mice (with two exceptions) had a mixed background of 56.25% C57, 12.5% B6, 18.75% SJL, and 12.5% Swiss-Webster and were derived from a cross between heterozygous mice carrying the mutant APPK670N, M671L gene (APPsw) with heterozygous PS1 (Tg line 6.2) mice. This resulted in offspring consisting of mutant APPsw, PS1, APPsw+PS1, and non-transgenic (NT) genotypes. The two exceptions were: 1) APPsw+PS1 mice used in the 7-day gavage treatment study, which had a C57/BL6/SJL background and were a gift from Karen Hsiao Ashe (University of Minnesota; Hsiao et al. 1996). All mice were maintained on a 12-hour dark and 12-hour light cycle with ad libitum access to rodent chow and water/caffeinated water. All animal procedures were performed in AAALAC-certified facilities under protocols approved by Institutional Animal Care and Use Committees at University of South Florida and the JA Haley VA Hospital.

General protocol

A spectrum of studies involving both acute and chronic caffeine administration was performed in APPsw/Tg2576 and APPsw+PS1 transgenic lines, with plasma, neurochemical, and/or behavioral measures collected. It should be underscored that these transgenic lines have measurable levels of soluble Aβ in both brain and plasma in young adulthood, with their brain levels of Aβ increasing appreciably during aging. This results in Aβ plaque formation beginning around 10–11 months of age for APPsw/Tg2576 mice and by 6 months of age for APPsw+PS1 mice. Thus, the 3–4 month-old APPsw/Tg2576 mice used in these studies had no Aβ deposition, while the 14 month and...
older APPsw mice exhibited age-dependent Aβ deposition. All APPsw+PS1 mice utilized in these studies were at least 15 months of age and therefore had robust Aβ deposition. The general protocol for each study is indicated below:

**Acute caffeine effects on plasma Aβ levels**

Acute (single treatment) administration of caffeine or saline vehicle was given by intraperitoneal (i.p.) injection or gavage to the following groups of mice: 3–4 month-old APPsw mice (i.p.), 14 month-old APPsw mice (i.p. or gavage), and 14 month-old APPsw+PS1 mice (gavage). A pre-treatment blood sample (0.15 ml) was taken by sub-mandibular vein puncture 3–4 days before treatment. At 3–4 hours following caffeine (1.5 mg/0.2 ml; Sigma, St. Louis, MO) or vehicle administration, another blood sample was taken. In these acute studies, each group of caffeine- or vehicle-treated animals consisted of 5–7 Tg mice. For all acute caffeine treatment studies, an equivalent volume of 0.9% saline (0.2 ml) was given immediately following any blood sample taken.

**Long-term caffeine effects on plasma Aβ levels**

Longer term caffeine administration was given by gavage to aged APPsw+PS1 mice. At 3–4 days following a pre-treatment blood sample, 15–20 month-old APPsw+PS1 mice (n = 6) were started on twice-daily caffeine treatment (1.5 mg/0.2 ml each) via gavage for 7 consecutive days. A blood sample was taken on the final day of caffeine treatment, as well as 9 days thereafter. A second group of four 20 month-old APPsw+PS1 mice were pre-treatment bled, and then given two caffeine treatments (1.5 mg/0.2 ml each) via gavage every 4th day for up to two months. In this second long-term study, blood samples were taken every 8th day during treatment, always on the day following a treatment. As was the case for acute studies, volume replacement with 0.9% saline occurred immediately following each blood sample.

**In vivo microdialysis: Acute caffeine effects on interstitial fluid (ISF) levels of Aβ in hippocampus**

**In vivo** microdialysis was used to assess brain ISF Aβγ40 in the hippocampus of awake, freely moving Tg2576 mice. Microdialysis was performed similar to previously described methods [14]. This technique samples soluble molecules within the extracellular fluid that are smaller than 38-kilodaltons, the molecular weight cut off of the probe membrane. Aβ capable of entering the probe has been dubbed “exchangeable Aβ or eAβγ” [14]. The pool of eAβ is in dynamic equilibrium with the total pool of ISF Aβ. During microdialysis, mice were housed in a constant light condition and remained awake with freedom of movement and *ad lib* food and water during microdialysis. Microdialysis perfusion buffer was artificial cerebrospinal fluid (CSF) containing 0.15% bovine serum albumin that was filtered through a 0.1 µm membrane. Flow rate was a constant 1.0 µl/minute, which recovers 23.4 ± 1.7% (mean ± SEM) of exchangeable Aβ within the brain ISF of Tg2576 mice. Samples were collected every 30–60 minutes with a refrigerated fraction collector into polypropylene tubes and assessed for Aβ by sandwich ELISA at the completion of each experiment, as described by Cirrito et al. [15]. Briefly, Aβx40 was assessed using an Aβx40-specific mouse monoclonal antibody, mHJ2, as a coating antibody and a biotinylated central domain antibody, mHJ5.1, as the detecting antibody, followed by streptavidin-poly-HRP-40 (Fitzgerald Industries, Concord, MA). All ELISA assays were developed using Super Slow ELISA TMB (Sigma) and absorbance read on a Bio-Tek FL-600 plate reader (Winooski, Vermont) at 650 nm. Basal levels of ISF Aβ were defined as the mean concentration of Aβ over 5–6 hours preceding drug treatment. The mean *in vivo* concentration of basal ISF eAβ was 3.9 ± 0.78 ng/ml (n = 6). For each animal, all Aβ levels were normalized to the basal Aβ concentration. Once basal ISF Aβ levels were established, Tg2576 mice were administered caffeine i.p. and ISF Aβ levels were sampled every 30 minutes until the end of the study. Mice were studied at 3 months of age, which is prior to Aβ deposition in this mouse model.

ISF Aβ half-life was determined similar to Cirrito et al. [14]. Microdialysis probes were inserted as described previously. Basal levels of ISF Aβ were established for five hours, followed by i.p. administration of 30 mg/kg caffeine or vehicle (PBS). Three hours after treatment, the γ-secretase inhibitor Compound E (Alexis Biochemicals, San Diego, CA; 100 nM) was added to the microdialysis perfusion buffer to rapidly inhibit Aβ production near the probe. The IC50 for this compound to inhibit γ-secretase activity *in vitro* is 0.3 nM. Microdialysis samples were collected every 30 minutes for an additional four hours and then assessed for Aβx40 by sandwich ELISA. The half-life of Aβ was calculated based on the slope of decline in ISF Aβ levels [14] beginning one hour after the onset of Compound E administration.
Long-term caffeine effects in behaviorally-tested mice

At 18–19 months of age, APPSw and NT littermate controls were pre-tested in the radial arm water maze (RAWM) task of working memory according to our established protocol [9,12,16]. Following confirmation that APPSw mice were cognitively-impaired, they were divided into two groups, with half of Tg mice started on caffeine administered in their drinking water (0.3 mg/ml, providing a daily dose of ≈ 1.5 mg caffeine/mouse) and the other half remaining on standard tap water, as detailed previously [9]. At 4–5 weeks into caffeine treatment, all mice were re-tested in the RAWM, with both last block and overall errors being analyzed for working memory Trials 4 and 5. Following completion of behavioral testing at 20–21 months of age, mice were deeply anesthetized with sodium pentobarbital, a blood sample was then taken for neurochemical analysis, followed by transcardial perfusion with 100 ml of 0.9% saline. Postmortem, both hippocampus and cerebral cortex were dissected and analyzed for soluble Aβ deposition, as previously described [17]. Briefly, equally-spaced 5-µm sections at the hippocampal level were immunostained for total Aβ deposition using a biotinylated human Aβ monoclonal antibody (clone 4G8; Covance Res. Products, Everyville, CA). Quantitative image analysis was then performed according to Mori et al. [18] and Aβ burden was determined as a percentage of immunolabeled area (positive pixels) relative to the full area captured (total pixels). Quantitative image analysis was done based on previous methods with modifications [18,19]. Images were acquired using an Olympus BX60 microscope with an attached digital camera system (DP-70, Olympus, Tokyo, Japan). The digital image was then routed into a Windows PC for quantitative analysis using SimplePCI software (Compix Inc., Imaging Systems, Cranberry Township, PA). Images of five 5-µm sections (150 µm apart) through the hippocampus were captured from each animal, and a threshold optical density was obtained that discriminated staining from background. Each region of interest was manually edited to eliminate artifacts. For Aβ burden analysis, data are report as percentage of immunolabeled area captured (positive pixels) relative to the full area captured (total pixels). Each analysis was done by a single examiner blinded to sample identities.

Plasma neurochemical analysis

Plasma from blood samples was analyzed for levels of Aβ1-40, caffeine, theophylline (a caffeine metabolite), and cytokines. Aβ1-40 levels were determined according to the aforementioned methodology involving brain tissues. Plasma caffeine and theophylline concentration were measured with ELISA Kits from Neogen (Lansing, MI, USA) by following the manufacture protocol. In brief, the enzyme conjugate solution was prepared by diluting the 180X enzyme conjugate stock 1 to 180 in the EIA buffer provided. Caffeine (or theophylline) standard was then diluted with EIA buffer at two fold dilutions from 200 ng/ml to 0.39 ng/ml. Then 20 µl standard of each dilution was added into the coated plate. Plasma samples were then diluted with EIA buffer, with 20 µl of this dilution added into the coated plate. Both standard and samples were run in duplicate in the plate. Both standard and samples were run in duplicate in the plate. Positive and negative controls of 20 µl were loaded to each plate. Then 180 µl of diluted drug-enzyme conjugate was added into each well and mixed by gently shaking the plate. Plates were covered with plastic film and incubated at room temperature for 45 minutes. During the incubation, a 10x wash buffer was diluted to 1X with DI water and mixed thoroughly. Once incubation was completed, the liquid was dumped from the wells. Plates were then taped on a clean lint-free towel to remove any remaining liquid in the wells. Then each well was washed with 300 µl of...
diluted wash buffer 3 times. After completing the last wash step, the bottom of the wells was wiped with a lint-free towel to remove any liquid on the outside of the wells. Then 150 µl of the K-Blue Substrate was added to each well with a multi-channel pipette. The plate was then mixed by gently shaking, followed by incubation at room temperature for 5 to 20 minutes. To stop the enzyme reaction, 50 µl of red stop solution was added to each well and gently mixed. The absorbance was then measured with plate reader (Synergy HT, Biotek, VT) at a wavelength of 650 nm. The absorbance was converted into concentration using Gen5 software.

Cytokine expression profiles were detected using the Bio-Plex kits (Bio-Rad, Richmond, CA, catalogue # 171F11181). Samples and standards were prepared using company protocols with the initial concentration of standards ranging from 32 ng/ml to 1.95 pg/ml. Plasma samples were prepared for analysis by diluting 1 volume of the serum sample with 3 volumes of the Bio-Plex mouse sample diluents. Details of this procedure were performed by followed the protocol provided by the manufacture. Finally, the plates were read. Each cytokine level was calculated based on its own standard curve. Brain cytokine and chemokine levels were detected with the same method.

Statistical analyses

Group comparisons involving levels of soluble/desorbed Aβ, caffeine, theophylline, and cytokines were performed using ANOVA. For determination of pre-treatment versus post-treatment differences in plasma Aβ level, paired t-tests were employed. All other statistical analyses are as indicated in the text. In order to test if relationships were present between plasma, neurochemical, and behavioral measures, correlation analysis was performed using the Systat analytical software package.

RESULTS

Acute caffeine administration reduces plasma Aβ level

We have previously found that Aβ1–40 and Aβ1–42 generation is decreased in N2a neuronal cell cultures following 6 hours of caffeine treatment [9]. Moreover, these reductions in generation of both Aβ1–40 and Aβ1–42 peptides were dose-dependent, occurring at caffeine concentrations (≤10 µM), which are typically present in plasma following coffee consumption in humans. Given the rapid delivery of caffeine to all body organs including the brain, we therefore hypothesized that acute caffeine administration would quickly suppress brain Aβ production in AD transgenic mice, resulting in a significant reduction in plasma Aβ levels within hours. In an initial study in which 3–4 month-old APPsw mice (pre-plaque) were given a single i.p. injection of caffeine (1.5 mg), plasma Aβ1–40 levels were significantly reduced by 41% at 3 hours post-treatment compared to pre-treatment levels (Fig. 2A); vehicle injection failed to affect plasma Aβ levels in other littermate APPsw mice. Caffeine-induced reductions in plasma Aβ1–40 levels were also observed in aged 14 month-old APPsw mice (plaque-bearing) at 3 hours following either a single i.p. or gavage treatment with the same dose of caffeine (Fig. 2B). Moreover, plasma caffeine concentrations in these same 14 month-old APPsw mice were negatively correlated with plasma Aβ1–40 levels; higher plasma caffeine levels were associated with lower plasma Aβ levels in individual animals (Fig. 2C). Even aged 19-month APPsw+PS1 mice (plaque-bearing) exhibited significant reductions in plasma Aβ1–40 levels at 3 hours following gavage treatment with caffeine (Fig. 2D).

Long-term oral caffeine treatment provides a sustained reduction in plasma Aβ levels

Our prior work has demonstrated that hippocampal levels of both soluble and insoluble Aβ are reduced by greater than 30% following 5½ months of oral caffeine treatment (~1.5 mg/day) to young adult APPsw mice [9]. In the same study, we also found this same treatment to be effective in reducing insoluble hippocampal Aβ levels in aged 17 month-old APPsw mice following 18 days of treatment. We therefore hypothesized that long-term oral caffeine treatment would result in a sustained suppression of plasma Aβ levels. In fact, aged 15–20 month-old APPsw mice (plaque-bearing) that were given oral treatment with 1.5 mg caffeine twice daily for one week did exhibit significant reductions in plasma levels of both Aβ1–40 and Aβ1–42 compared to pre-treatment values (Fig. 2E). At 9 days following cessation of this caffeine treatment, however, plasma levels of both Aβ1–40 and Aβ1–42 had returned to their pre-treatment levels. In a second long-term treatment study, 20 month-old APPsw+PS1 mice (plaque-bearing) were given oral caffeine treatment (1.5 mg) twice daily every 4th day over a 2 month period. Periodic analysis of plasma Aβ1–40 and Aβ1–42 levels during this treatment period revealed not
C. Cao et al. / Caffeine Suppresses Amyloid-β Levels in Plasma and Brain of Alzheimer’s Disease Transgenic Mice

Fig. 2. Caffeine treatment induces a rapid and sustained decrease in plasma Aβ levels. (A,B,D) A single i.p. or gavage treatment with caffeine significantly reduces plasma Aβ levels in 3–4 month-old (A) and 14 month-old (B) APPsw mice; as well as in 19 month-old APP+PS1 mice (D). In all three studies, saline vehicle treatment had no effect. (C) Plasma caffeine levels in 14M old APPsw mice are inversely correlated with plasma Aβ1−40 levels. (E) Oral caffeine treatment for one week to 15–20 month-old APPsw mice results in decreased plasma levels of both Aβ1−40 and Aβ1−42 immediately following treatment, with a rebound in plasma Aβ levels occurring by 9 days after cessation of caffeine treatment. Each group in A, B, D, and E consisted of 5–10 mice. (F) As exemplified by two aged 20 month-old APP+PS1 mice, oral caffeine administration every 4th day over a 2-month period induces a sustained and continual decrease in plasma levels of both Aβ1−40 and Aβ1−42 over the treatment period. Post-treatment versus pre- or delayed post-treatment Aβ levels were evaluated by paired t-tests. *p < 0.05–0.01 versus pre-treatment levels; **p < 0.05 versus both pre-treatment and 9-day post-treatment levels. (Colours are visible in the electronic version of the article at www.iospress.nl.)
Fig. 3. Caffeine lowers interstitial fluid (ISF) Aβ levels. (A) Brain ISF Aβ_{40} levels were measured by in vivo microdialysis. Prior to treatment with caffeine, ISF Aβ levels fluctuated very little. A low dose (5 mg/kg) and a higher dose (30 mg/kg) of caffeine caused ISF Aβ levels to decrease significantly compared to basal levels. (B) Following a 5 mg/kg dose of caffeine i.p., ISF Aβ_{40} levels decreased by 19% compared to basal levels (*p < 0.05), while a 30 mg/kg administration decreased Aβ levels by 33% (* *p < 0.01, n = 6 per group). The mean concentration of ISF Aβ represents an average of hours 2–3 after each dose of caffeine when Aβ levels had stabilized. (C) Tg2576 were pre-treated with vehicle or 30 mg/kg caffeine for 3 hours (n = 6 per group), followed by administration of 100 nM Compound E, a γ-secretase inhibitor, via reverse microdialysis. In both groups, ISF Aβ levels decreased rapidly when APP cleavage was blocked. (D) The elimination half-life of ISF Aβ_{40} was comparable in vehicle-treated and caffeine-treated mice, suggesting that caffeine does not affect ISF Aβ elimination, but likely impacts Aβ production instead. (Colours are visible in the electronic version of the article at www.iospress.nl.)

only a sustained reduction in both Aβ peptides, but also a continuing decrease in their levels throughout the 2-month treatment. Given that the half-life of caffeine in rodents is only 0.7 to 1.2 hours [3], these later observations suggest that the effects of caffeine on Aβ suppression greatly exceed its own half-life.

Caffeine administration lowers brain interstitial fluid levels of Aβ in vivo

Aβ is primarily produced in neurons and secreted into the brain extracellular space where it is normally soluble within ISF. To determine if caffeine administration acutely affects brain ISF Aβ levels, 3 month-old Tg2576 mice (pre-Aβ plaque) were treated with several doses of caffeine during in vivo microdialysis to measure ISF Aβ levels. Microdialysis probes were implanted into the hippocampus, permitting us to sample ISF Aβ levels every 30 minutes for up to 24 hours in awake, behaving animals [14,15]. Basal ISF Aβ levels were determined over 6 hours in each mouse followed by i.p. administration of caffeine at 5 mg/kg (∼0.15 mg/mouse), then at 30 mg/kg (∼1 mg/mouse)
Fig. 4. Long-term caffeine administration to aged, cognitively-impaired APPsw mice reduces soluble Aβ levels in both cortex and hippocampus, while also decreasing deposited (insoluble) Aβ in hippocampus. Caffeine was administered to 18–19 month-old APPsw mice for two months in their drinking water. Both brain Aβ1−40 and Aβ1−42 were decreased in caffeine-treated Tg mice. Although plasma Aβ levels were unaffected for all Tg/Caff mice inclusively, see Fig. 7B. Immunohistochemical Aβ deposition in the hippocampus was reduced by 40% in caffeine treatment mice. *p < 0.05; **p < 0.001. Each group consisted of 5–8 mice. (Colours are visible in the electronic version of the article at www.iospress.nl.)

Long-term oral caffeine treatment to aged, cognitively-impaired APPsw mice reduces brain soluble and deposited Aβ

To determine the effects of chronic caffeine treatment in cognitively-impaired AD mice, caffeine (~1.5 mg/day) was orally administered in drinking water to 18–19 month-old APPsw mice (plaque-bearing) that were confirmed to be impaired in the RAWM task of working memory prior to treatment. At 4–5 weeks into caffeine treatment, impaired APPsw mice that had been given caffeine (Tg/Caff) exhibited substantially better RAWM working memory performance compared to the continuing impairment of control APPsw mice [12]. After euthanization at 20–21 months of age (2 months into caffeine treatment), soluble Aβ1−42 levels in both cortex and hippocampus of Tg/Caff mice were significantly reduced by 51% and 59%, respectively, compared to Tg controls (Fig. 4A). Cortical and hippocampal Aβ1−40 levels were also reduced by chronic caffeine treatment, although the decrease in hippocampal Aβ1−40 did not reach statistical significance (p = 0.09). Compared to Tg controls, plasma Aβ1−40 levels were not significantly decreased in Tg/Caff mice. However, when Tg/Caff mice were divided into two sub-groups based on higher versus lower plasma caffeine levels, a significant decrease in plasma Aβ1−40...
C. Cao et al. / Caffeine Suppresses Amyloid-β Levels in Plasma and Brain of Alzheimer’s Disease Transgenic Mice

was evident in higher plasma caffeine mice (see section below). Finally, and in the same behaviorally-tested aged Tg mice, chronic caffeine treatment resulted in a remarkable 40% reduction in hippocampal Aβ deposition compared to Tg controls (Fig. 4B). Brain levels of insoluble Aβ (as measured by ELISA) were also reduced in caffeine-treated Tg mice, as exemplified by the 29% and 33% decreases in Aβ1–40 and Aβ1–42, respectively, seen in posterior cortex (data not shown).

**Plasma Aβ levels do not correlate with brain Aβ levels or cognitive performance in aged APPsw mice**

To explore the relationship between brain and plasma pool of Aβ, as well as the association between various Aβ pools and cognitive performance, we next performed correlation analysis between these measures in the same aged APPsw mice whose brain and plasma Aβ measures were presented in Fig. 4. These 20–21 month-old APPsw mice exhibited strong correlations between Aβ1–40 and Aβ1–42 levels in hippocampus and cortex, and for both soluble and insoluble Aβ pools (Fig. 5A and B). These correlations were present irrespective of whether all Tg mice, or only Tg controls were included. In sharp contrast, plasma Aβ1–40 was not correlated with any of the 8 brain Aβ measures evaluated (e.g., hippocampus or cortex, soluble or insoluble, Aβ1–40 or Aβ1–42). Figure 5C and D shows two representative plots involving hippocampal soluble/insoluble Aβ1–40 versus plasma Aβ1–40. The lack of correlations between brain and plasma Aβ measures was present irrespective of whether all Tg mice, or only Tg controls were included. Finally, there were no correlations between plasma Aβ1–40 levels and four measures of cognitive performance in the RAWM task of working memory; two of these correlations are shown in Fig. 6 (A and B). However, as we have consistently shown in prior studies [22–25], Aβ levels in cerebral cortex, entorhinal cortex, and hippocampus were closely linked to RAWM performance; higher brain Aβ lev-
els were strongly correlated with poorer working memory performance (Fig. 6C and D). Thus, plasma levels of Aβ are not an accurate index of: 1) soluble or insoluble brain Aβ; or 2) cognitive performance.

The relationship between plasma caffeine levels in aged APPsw mice and their plasma/brain Aβ levels and cognitive performance

Plasma taken at euthanasia from the 6 behaviorally-tested 20–21 month-old APPsw mice that have been given oral caffeine treatment for two months was analyzed for concentrations of caffeine and theophylline (a major biologically-active metabolite of caffeine). A strong inverse correlation was evident between plasma caffeine concentration in those mice and their plasma levels of Aβ1−40 (Fig. 7A), with higher plasma caffeine levels associated with lower plasma Aβ levels. Because there was a significant range in plasma caffeine concentrations among these animals, the three APPsw mice with the highest plasma caffeine levels [mean = 9331 ng/ml] were compared to the three mice with the lowest levels for plasma Aβ levels [mean = 769 ng/ml]. Mice with higher plasma caffeine levels had significantly reduced plasma Aβ1−40 levels compared to those with lower plasma caffeine levels (Fig. 7B). However, plasma caffeine levels in these APPsw mice were not correlated with their Aβ1−40 or Aβ1−42 levels in either hippocampus or cerebral cortex (data not shown). Moreover, as was the case for plasma Aβ levels (Fig. 6A and B), there were no correlations between plasma caffeine levels and RAWM working memory performance in aged APPsw mice (Fig. 7C and D). Plasma caffeine levels were, however, strongly correlated with plasma levels of theophylline (Fig. 7E). Importantly for human relevance, the 6 aged APPsw mice chronically treated with caffeine had a mean plasma caffeine concentration of 26 ± 11.5 µM, which is com-
Fig. 7. Effects of caffeine and theophylline on plasma, brain, and cognitive measures. In aged 20–21 month-old APPsw mice that had been treated for 2 months with caffeine and cognitively evaluated (n = 6), blood and brain tissues taken at euthanasia were analyzed. (A) High plasma caffeine levels correlated with lower plasma Aβ levels. (B) Mice with higher plasma caffeine levels had lower plasma Aβ1–40 levels and lower hippocampal cytokine levels than those mice with lower caffeine levels. ∗p < 0.05; ∗∗p < 0.01. (C,D) As exemplified by these 2 correlation graphs, plasma caffeine levels in individual mice were not correlated with their radial arm water maze (RAWM) working memory performance. (E) Plasma caffeine and plasma theophylline levels were strongly correlated. (F) High plasma theophylline levels correlated with lower plasma IFN-γ levels. (Colours are visible in the electronic version of the article at www.iospress.nl.)

parable to plasma caffeine levels in humans following several cups of coffee [3].

The association of Aβ and caffeine levels in plasma with cytokines in plasma/brain

Aβ and caffeine have been reported to have pro- and anti-inflammatory actions, respectively [20,26]. Therefore, we investigated whether plasma levels of these two compounds impacted plasma or brain cytokine levels in aged APPsw mice (plaque-bearing) following two months of oral caffeine treatment. Plasma Aβ1–40 levels were not correlated with plasma cytokine levels for all Tg mice collectively, irrespectively of caffeine treatment (data not shown). Additionally, plasma caffeine levels in caffeine-treated Tg mice were not correlated with plasma cytokine levels (data not shown). Indeed, there were largely no differences in “plasma” cytokine levels between non-transgenic, Tg, and Tg/Caff groups in this study (data not shown). Although this was also the case for “brain” cytokine levels, closer inspection revealed potential effects of caffeine on levels of key
inflammatory cytokines. Specifically among caffeine-treated Tg mice, those mice with higher caffeine levels had significantly reduced levels of hippocampal cytokines compared to mice with lower caffeine levels (Fig. 7B). These results suggest an anti-inflammatory action of caffeine in a key brain area for cognitive function. The caffeine metabolite “theophylline” may also be contributory to the anti-inflammatory effect of caffeine, as exemplified by the lower levels of plasma interferon (IFN)-γ in APPsw mice having higher plasma theophylline levels (Fig. 7F). Indeed, plasma levels of theophylline in caffeine-treated APPsw mice: 1) were correlated with lower cytokine levels in both hippocampus and cortex; and 2) showed the same anti-inflammatory profile as caffeine (Fig. 7B) when analyzed in terms of high vs. low theophylline levels (data not shown).

DISCUSSION

In this report, we show that caffeine treatment to AD transgenic mice lowers Aβ levels in plasma and brain ISF within a few hours and can provide continued reductions in plasma Aβ through oral treatment periods of 1-8 weeks. Even in aged, cognitively-impaired APPsw mice bearing pre-existing and substantial Aβ burdens, oral caffeine administration over several months reduced both soluble and deposited brain Aβ. Relatedly, this same caffeine treatment reverses the poor memory performance of aged APPsw mice back to the level of non-transgenic (normal) mice [12]. However, because there were no correlations between hippocampal and plasma Aβ levels in individual mice, we conclude that plasma Aβ levels are not an accurate index of brain Aβ levels in aged AD mice. Moreover, because there were no correlations between plasma Aβ levels and cognitive performance in the same aged AD mice, we conclude that blood Aβ levels are not an accurate index of cognitive performance. From an overall perspective, then, plasma Aβ levels are not a viable biomarker for the cognitive and neurochemical characteristics of aged AD mice. The inability of plasma Aβ1−40 levels to acutely reflect decreased brain Aβ1−40 levels may involve a consequent, acute decrease in Aβ1−40 transporter activity (below saturability levels) at the blood brain barrier [27]. Secondly, our collective results underscore that caffeine, its metabolites, and/or analogs should be considered for prevention and treatment trials in AD because caffeine can suppress Aβ production, but not its clearance from the brain.

The concentration of Aβ in brain tissue and CSF is some 50–100 times higher than in plasma [28]. It is thus likely that a sizable amount of plasma Aβ1−40 originates from production in, and out of, the brain. Indeed, Aβ is rapidly produced and cleared from the brain, with similar ISF clearance rates in AD mice and humans [13,14]. Given the relatively short (<2 hours) half-life of ISF Aβ in AD mice [14], it is apparent that newly produced Aβ enters a dynamic equilibrium between soluble and insoluble/deposited Aβ in the brain, with continual transport of soluble Aβ out of the brain and into plasma (Fig. 1, Unmodulated). In the present study, a single treatment with caffeine rapidly reduced both brain ISF and plasma levels of Aβ1−40 within several hours, indicating a direct and immediate effect of caffeine on brain Aβ levels. Alternatively, because blood platelets appear to be the primary source of circulating APP and Aβ, it is possible that caffeine was independently lowering plasma Aβ by suppressing Aβ production from blood platelets. The peripheral production of Aβ could certainly be one explanation for the lack of correlations between plasma and brain Aβ or between plasma Aβ and any behavioral/neurochemical markers evaluated in this study.

A single treatment with caffeine did not affect the half-life of ISF Aβ, demonstrating that caffeine had affected brain Aβ production rather than its elimination. Underscoring this premise, our prior studies [9,12] show that caffeine affects Aβ production through suppression of both β-secretase (BACE1) and γ-secretase/PS1 expression. Whether or not this caffeine-induced suppression of Aβ production is direct or involves adenosine receptor blockade/mediation is currently unknown and a subject of current research in our laboratories. Acutely, such decreased Aβ production would result in lower soluble Aβ in brain ISF and consequently lower plasma Aβ levels (Fig. 1, Caffeine – Short-Term). This is exactly what we observed in AD mice that were young adults (no brain Aβ deposition), as well as aged AD mice (robust Aβ deposition). It is noteworthy that even caffeine treatment every fourth day was sufficient to provide a sustained reduction in plasma Aβ levels to aged AD mice over several months. Thus, the Aβ-reducing effects of caffeine exceed its own half-life, which does not preclude adenosine receptor-mediated effects of caffeine. Indeed, adenosine receptor activation has been shown to impact gene expression/signal transduction [3].

We recently reported that caffeine, when administered in drinking water from young adulthood through older age, protected APPsw mice from otherwise cer-
tained impairment and reduced their brain Aβ levels [9]. These results, suggestive that moderate daily intake of caffeine (the human equivalent of 5 cups of coffee daily) could delay or reduce the risk of AD, underscore epidemiologic studies reporting that caffeine is protective against both AD [7] and cognitive impairment associated with normal aging [5,6,8]. In a new study [12], we show that this same caffeine treatment paradigm, when given for two months to cognitively-impaired APPsw mice, reverses their working memory impairment to normal levels. We further report that this 2-month caffeine administration regime, given to aged APPsw mice with pre-existing and substantial Aβ burdens, reduces both soluble and deposited brain Aβ levels—in essence, reversing their brain Aβ neuropathology. Although the mechanism(s) for caffeine-induced reversal of Aβ deposition requires further investigation, we hypothesize that “chronic” caffeine suppresses Aβ production long-term, resulting in consistently lower brain levels of soluble ISF Aβ (Fig. 1, Caffeine – Long-Term). This would then induce a flux of insoluble Aβ out of the deposited form and into the soluble form due to dynamic equilibrium. Newly-solubilized Aβ would then be cleared into the plasma via both blood-brain-barrier transport and bulk fluid flow. The dynamic equilibrium between soluble (ISF) and insoluble/deposited Aβ in the brain is highlighted by our earlier work showing that young adult and aged APPsw mice had similar steady-state levels of ISF Aβ, but rapid inhibition of Aβ production resulted in a two-fold longer Aβ half-life in the aged, Aβ deposit-bearing mice [14]. We believe this longer Aβ half-life is caused by solubilization of a portion of the deposited Aβ pool due to the dynamic ISF Aβ ↔ deposited Aβ equilibrium.

In contrast to caffeine’s clear ability to reduce brain Aβ levels through chronic two-month treatment to aged Tg mice, these same mice did not have significantly reduced Aβ levels in their plasma. However, correlation analysis revealed not only a strong inverse correlation between plasma caffeine levels and plasma Aβ levels in these aged Tg mice, but also a differential effect of high versus low plasma caffeine levels: aged Tg mice with high plasma caffeine levels had significantly reduced plasma Aβ levels compared to those with low plasma caffeine levels. Thus, whether or not a chronic reduction in plasma Aβ levels occurs in aged Tg mice would appear to be dependent on plasma caffeine levels. Our elucidation of the same inverse correlation between plasma caffeine and plasma Aβ in young adult Tg mice given a single caffeine treatment indicates that this relationship transcends: 1) length of caffeine treatment; 2) age of AD mouse recipient; and 3) whether or not Aβ plaques are present. Indeed, given the fact that plasma caffeine concentrations in both age groups were well within physiologic range, it would not be surprising for a similar inverse relationship between plasma caffeine and plasma Aβ to be present in humans. In the context that caffeine suppresses γ-secretase [9,12], the reduced plasma Aβ1–40 levels seen in our aged APPsw mice with higher plasma caffeine levels is consistent with the reported reduction of plasma Aβ levels in AD patients following a similar 6-week treatment with a γ-secretase inhibitor [29].

For aged APPsw mice, strong correlations were evident between Aβ1–40 and Aβ1–42 levels (both soluble and insoluble) in hippocampus and cortex irrespective of caffeine treatment. Moreover, we have found brain Aβ levels from aged APPsw mice to be strongly correlated with cognitive impairment [12,23–25]. Thus, our prior work has established an intimate and presumably causative association between “brain” Aβ levels and cognitive impairment. In sharp contrast, results from the present study in the aged APPsw mice clearly show that no such relationship exists between “plasma” Aβ levels and cognitive performance. Furthermore, plasma Aβ levels in these mice were not correlated with any of eight brain Aβ measures. We conclude that, at least in aged AD transgenic mice, plasma Aβ levels are not an accurate index of soluble or insoluble brain Aβ levels, nor are they an accurate index of cognitive performance. This conclusion is consistent with a previous study in old APP transgenic mice [30], as well as a recent report showing that plasma Aβ levels in AD patients did not correlate with Aβ levels measured in neocortex following death [31] nor with brain Aβ burden as measured in vivo with amyloid imaging [32]. As with plasma Aβ, we also found no correlations between plasma caffeine concentrations and brain Aβ levels or cognitive performance. Thus, higher plasma caffeine levels were associated with lower plasma Aβ levels, but were not reflective of brain Aβ levels or cognitive performance.

From the present studies involving several AD transgenic lines, it is apparent that baseline plasma levels of Aβ remain relatively stable during aging and irrespective of APPsw versus APPsw+PS1 transgenicity (Figs 2 and 4). This finding suggests either close regulation of plasma Aβ in AD transgenic mice or limited/saturable Aβ transport into the blood. Regarding the latter, we propose that during aging in AD mice, there is a limit to the amount of Aβ that can be transported out of the brain and into plasma. After this lim-
plasma caffeine levels. As with plasma caffeine levels, however, no correlations were evident between plasma theophylline and plasma Aβ or cognitive performance. Predictably, plasma theophylline levels were tightly correlated with plasma caffeine levels. As with plasma caffeine levels, however, no correlations were evident between plasma theophylline and plasma Aβ or cognitive performance. As one of several active metabolites of caffeine, theophylline may be responsible for a significant portion of the cognitive, neuropathologic, and neurochemical benefits of caffeine. This premise is underscored by the fact that caffeine metabolites such as theophylline have a considerably longer half-life than caffeine. Indeed, brain concentrations of theophylline in mice following long-term caffeine ingestion are usually higher than those of caffeine [36]. We are currently exploring the contribution of such caffeine metabolites to the benefits currently being attributed to caffeine in our AD mice.

No correlations were found between plasma Aβ levels and plasma/brain cytokine levels, suggesting their independence of one another. Although plasma caffeine levels were also not correlated with plasma cytokines, a clear reduction in hippocampal inflammatory cytokines was evident for caffeine-treated mice with higher plasma caffeine levels compared to those with lower caffeine levels. This was not only also true for plasma theophylline levels, but higher plasma theophylline levels were strongly and consistently correlated with lower inflammatory cytokine levels in both hippocampus and cortex; these theophylline findings suggest a more profound interaction between this caffeine metabolite and brain cytokines than caffeine itself, perhaps due to the aforementioned higher brain concentrations of theophylline [36]. The ability of caffeine and theophylline to provide beneficial anti-inflammatory effects in the brain of AD mice is consistent with a large body of data supportive of their anti-inflammatory capacities [20] and, as such, could represent a potent “non-amyloidogenic” mechanism of caffeine action that may contribute to its ability to protect against/reverse cognitive impairment and synaptic dysfunction. Other such beneficial mechanisms of caffeine action in AD mice (and perhaps in human AD) include the antioxidant actions caffeine [37], its ability to block disruptions of the blood-brain barrier [38], and its well-established antagonism of brain A1 and/or A2a adenosine receptors [1,2,39,40]. Indeed, adenosine receptor antagonism may be central to most or all of the beneficial actions of caffeine against AD and any combination of “caffeinergic” actions may collectively provide the cognitive benefits we have documented in AD mice.

Anti-AD drugs currently on the market (cholinesterase inhibitors and NMDA receptor antagonists) have minimal benefits and do not appear to address AD pathogenesis. Although caffeine is the most widely consumed psychoactive agent in the world, its intake in Western countries decreases substantially during aging. Given that: 1) blood caffeine concentrations equilibrate almost instantaneously with brain caffeine levels [3]; 2) caffeine appears to suppress AD pathogenesis [9,12]; 3) caffeine has few, if any, deleterious side effects for most individuals [10]; and 4) caffeine is readily available and inexpensive, therapeutic actions of this psy-
choactivating agent against AD could provide immediate benefits. Based on the robust protective [9] and treatment effects [12] of caffeine that we have observed in AD transgenic mice, Phase II clinical trials involving acute caffeine administration are currently in progress. To our knowledge, no prior studies have investigated the effect of acute or chronic caffeine administration on plasma biomarkers related to AD. It is important to note that this report’s acute caffeine administration studies involved AD transgenic mice “naïve” to caffeine, whereas clinical trials involve many occasional or habitual caffeine users. Therefore, it is difficult to predict the impact of acute caffeine administration in these ongoing human trials.

To summarize, the present report demonstrates that caffeine can acutely decrease brain and plasma Aβ levels, as well as reduce brain Aβ deposition and improve cognitive function following chronic administration. As such, caffeine appears to have excellent potential as a safe and effective therapeutic against AD. We also provide evidence from multiple studies and methodologies indicating that plasma Aβ is not an accurate index of brain Aβ levels/deposition or cognitive performance in aged AD mice.

ACKNOWLEDGMENTS

This research was supported by grants to G.W.A. and H.P. within the NIA-designated Florida Alzheimer’s Disease Research Center (P50AG025711), AG029524 (J.R.C.), AG13956 (D.M.H.), Cure Alzheimer’s Fund Disease Research Center (P50AG025711), AG029524 (H.P. within the NIA-designated Florida Alzheimer’s Center & Research Institute.

REFERENCES


